Enrollment
Patients enrolled in the PRAETORIAN trial were approached for an extended follow-up duration of 48 additional months.
Duration of the Study
The extended follow-up started on 01 December 2019 and ended after 48 months on 01 December 2023.
Participating Centers
All centers who were active in the PRAETORIAN trial were approached to prolong their participation.
Results
Results of the study were presented as a late breaking trial at the HRS 2025 conference. The data are published in Circulation. Results can also be found here.
The PRAETORIAN trial is registered with ClinicalTrials.gov (NCT01296022).